Title:
BIOMARKER COMPOSITION FOR PREDICTING CANCER PATIENT SUSCEPTIBILITY TO ANTI-IGSF1 ANTIBODY, AND METHOD USING SAME
Document Type and Number:
WIPO Patent Application WO/2023/211073
Kind Code:
A1
Abstract:
The present invention relates to: a biomarker composition for predicting cancer patient susceptibility to an anti-IGSF1 antibody; and a method for providing information required for predicting cancer patient susceptibility to an anti-IGSF1 antibody by using same. Therefore, individual cancer patient susceptibility to an anti-IGSF1 antibody can be accurately predicted before treatment through a method for measuring the expression level of PD-L1 protein or a gene encoding same, and thus an anticancer drug with a high therapeutic effect can be selected, and side effects caused by using unnecessary anticancer drugs can be prevented.
Inventors:
KIM SEONG-RAK (KR)
PARK YOON-SUN (KR)
JIN SOLL (KR)
BAE SEUNG-GEON (KR)
KIM DA-EUN (KR)
LEE YEO-JIN (KR)
CHOI YEON-SEOUNG (KR)
PARK YOON-SUN (KR)
JIN SOLL (KR)
BAE SEUNG-GEON (KR)
KIM DA-EUN (KR)
LEE YEO-JIN (KR)
CHOI YEON-SEOUNG (KR)
Application Number:
PCT/KR2023/005499
Publication Date:
November 02, 2023
Filing Date:
April 21, 2023
Export Citation:
Assignee:
WELLMARKER BIO CO LTD (KR)
International Classes:
G01N33/574; C12Q1/6886
Domestic Patent References:
| WO2021201571A1 | 2021-10-07 |
Foreign References:
| US20190128892A1 | 2019-05-02 | |||
| KR101811731B1 | 2018-01-25 |
Other References:
SEUNGDEOK LEE: "Well Marker Bio-Samsung Bio Immuno-oncology CDMO Contract Signed. ", MEDICAL NEWSPAPER, 15 March 2021 (2021-03-15), XP093103219, Retrieved from the Internet [retrieved on 20231120]
YAOYAO GUAN; YINGHAO WANG; ADHEESH BHANDARI; ERJIE XIA; OUCHEN WANG: "IGSF1: A novel oncogene regulates the thyroid cancer progression", CELL BIOCHEMISTRY AND FUNCTION., BUTTERWORTH, GUILDFORD., GB, vol. 37, no. 7, 25 July 2019 (2019-07-25), GB , pages 516 - 524, XP071523442, ISSN: 0263-6484, DOI: 10.1002/cbf.3426
WELLMARKER BIO: "Wellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)", CISION PR NEWSWIRE, 7 February 2023 (2023-02-07), XP093103218, Retrieved from the Internet [retrieved on 20231120]
CHUNGMAN LEE: "GSK Invests about 1 Trillion KRW to Develop Next-generation Immune Anti-cancer Drugs in Earnest. ", HEALTH KOREA NEWS, 5 April 2023 (2023-04-05), XP093103220, Retrieved from the Internet [retrieved on 20231120]
YAOYAO GUAN; YINGHAO WANG; ADHEESH BHANDARI; ERJIE XIA; OUCHEN WANG: "IGSF1: A novel oncogene regulates the thyroid cancer progression", CELL BIOCHEMISTRY AND FUNCTION., BUTTERWORTH, GUILDFORD., GB, vol. 37, no. 7, 25 July 2019 (2019-07-25), GB , pages 516 - 524, XP071523442, ISSN: 0263-6484, DOI: 10.1002/cbf.3426
WELLMARKER BIO: "Wellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)", CISION PR NEWSWIRE, 7 February 2023 (2023-02-07), XP093103218, Retrieved from the Internet
CHUNGMAN LEE: "GSK Invests about 1 Trillion KRW to Develop Next-generation Immune Anti-cancer Drugs in Earnest. ", HEALTH KOREA NEWS, 5 April 2023 (2023-04-05), XP093103220, Retrieved from the Internet
Attorney, Agent or Firm:
RYU, Jong Woo et al. (KR)
Download PDF: